Dr Lisa Horvath

2023, 'Cell-Type-Specific Signalling Networks Impacted by Prostate Epithelial-Stromal Intercellular Communication', Cancers, 15, http://dx.doi.org/10.3390/cancers15030699

2023, 'Characteristics of immune-infiltrating cells in the tumor microenvironment of appendiceal cancer with peritoneal disease.', Journal of Clinical Oncology, 41, pp. 217 - 217, http://dx.doi.org/10.1200/jco.2023.41.4_suppl.217

2023, 'Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts', Molecular Oncology, 17, pp. 469 - 486, http://dx.doi.org/10.1002/1878-0261.13376

2023, 'Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022', European Urology, 83, pp. 267 - 293, http://dx.doi.org/10.1016/j.eururo.2022.11.002

2023, 'Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022', European Journal of Cancer, 185, pp. 178 - 215, http://dx.doi.org/10.1016/j.ejca.2023.02.018

2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074

2023, 'Targeting lipid metabolism in metastatic prostate cancer', Therapeutic Advances in Medical Oncology, 15, http://dx.doi.org/10.1177/17588359231152839

2023, 'Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial', The Lancet Oncology, 24, pp. 323 - 334, http://dx.doi.org/10.1016/S1470-2045(23)00063-3

2022, '1409P Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention', Annals of Oncology, 33, pp. S1189 - S1189, http://dx.doi.org/10.1016/j.annonc.2022.07.1895

2022, 'African-specific molecular taxonomy of prostate cancer', Nature, 609, pp. 552 - 559, http://dx.doi.org/10.1038/s41586-022-05154-6

2022, 'Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients', Clinical Autonomic Research, 32, pp. 497 - 506, http://dx.doi.org/10.1007/s10286-022-00895-w

2022, 'Cardio-Oncology Recommendations for Pediatric Oncology Patients', JACC: Advances, 1, pp. 100155 - 100155, http://dx.doi.org/10.1016/j.jacadv.2022.100155

2022, 'Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer', BMC Medicine, 20, pp. 112, http://dx.doi.org/10.1186/s12916-022-02298-0

2022, 'Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality', CLINICAL AND TRANSLATIONAL MEDICINE, 12, http://dx.doi.org/10.1002/ctm2.1030

2022, 'GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)', Therapeutic Advances in Medical Oncology, 14, http://dx.doi.org/10.1177/17588359221092486

2022, 'Harnessing the Heterogeneity of Prostate Cancer for Target Discovery Using Patient-Derived Explants', Cancers, 14, http://dx.doi.org/10.3390/cancers14071708

2022, 'Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP', Journal of Clinical Oncology, 40, pp. 837 - 846, http://dx.doi.org/10.1200/JCO.21.00941

2022, 'Managing advanced prostate cancer in the Asia Pacific region: “Real-world” application of Advanced Prostate Cancer Consensus Conference 2019 statements', Asia-Pacific Journal of Clinical Oncology, 18, pp. 686 - 695, http://dx.doi.org/10.1111/ajco.13722

2022, 'Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin', Cancers, 14, http://dx.doi.org/10.3390/cancers14194792

2022, 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial', The Lancet Oncology, 23, pp. 362 - 373, http://dx.doi.org/10.1016/S1470-2045(21)00757-9

2022, 'Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial', European Journal of Cancer, 160, pp. 61 - 71, http://dx.doi.org/10.1016/j.ejca.2021.09.043

2022, 'Preface: Novel Therapeutic Targets and Biomarkers in Prostate Cancer', Critical Reviews in Oncogenesis, 27, pp. vii - ix, http://dx.doi.org/10.1615/CritRevOncog.2022043661

2022, 'Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming', Cellular Oncology, 45, pp. 1311 - 1328, http://dx.doi.org/10.1007/s13402-022-00719-z

2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y

2022, 'The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions', Therapeutic Advances in Medical Oncology, 14, pp. 17588359221112478, http://dx.doi.org/10.1177/17588359221112478

Strach MC; Yeung N; Apostolov E; Lin H-M; Nagaraju RT; Ansari N; Koh C; Shin J-S; Kench J; Aziz O; Swarbrick A; Horvath LG; Barriuso J; Mahon K, 2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', ANNALS OF ONCOLOGY, vol. 33, pp. S1322 - S1322, http://dx.doi.org/10.1016/j.annonc.2022.07.1791

Tie J; Cohen J; Lahouel K; Lo SN; Wang Y; Wong R; Shapiro J; Harris S; Khattak A; Burge M; Horvath LG; Karapetis CS; Shannon J; Singh M; Yip D; Papadopoulos N; Tomasetti C; Kinzler K; Vogelstein B; Gibbs P, 2022, 'Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)', ANNALS OF ONCOLOGY, vol. 33, pp. S683 - S683, http://dx.doi.org/10.1016/j.annonc.2022.07.456

2021, 'A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours', Cancer Chemotherapy and Pharmacology, 87, pp. 613 - 620, http://dx.doi.org/10.1007/s00280-020-04225-7

2021, 'Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer', Prostate Cancer and Prostatic Diseases, 24, pp. 860 - 870, http://dx.doi.org/10.1038/s41391-021-00338-z

2021, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', Genome Medicine, 13, pp. 81, http://dx.doi.org/10.1186/s13073-021-00885-z

2021, 'Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer', JCO oncology practice, 17, pp. e204 - e216, http://dx.doi.org/10.1200/OP.20.00399

2021, 'Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growth', Journal of Pathology, 254, pp. 135 - 146, http://dx.doi.org/10.1002/path.5665

2021, 'Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status', Science Advances, 7, http://dx.doi.org/10.1126/sciadv.abh0363

2021, 'Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition', Cancer Research, 81, pp. 4981 - 4993, http://dx.doi.org/10.1158/0008-5472.CAN-20-3863

2021, 'Mainstream consent programs for genetic counseling in cancer patients: A systematic review', Asia-Pacific Journal of Clinical Oncology, 17, pp. 163 - 177, http://dx.doi.org/10.1111/ajco.13334

2021, 'Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer', Frontiers in Immunology, 12, http://dx.doi.org/10.3389/fimmu.2021.641307

2021, 'Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy', European Urology, 80, pp. 275 - 279, http://dx.doi.org/10.1016/j.eururo.2021.05.016

2021, 'Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase', EBioMedicine, 72, http://dx.doi.org/10.1016/j.ebiom.2021.103625

2021, 'Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic', JOURNAL OF TELEMEDICINE AND TELECARE, http://dx.doi.org/10.1177/1357633X211045586

2021, 'Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic', Journal of Telemedicine and Telecare, http://dx.doi.org/10.1177/1357633X211045586

2021, 'Plasma cell-free dna profiling of pten-pi3kakt pathway aberrations in metastatic castration-resistant prostate cancer', JCO Precision Oncology, 5, pp. 622 - 637, http://dx.doi.org/10.1200/PO.20.00424

2021, 'Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer', European Urology Focus, 7, pp. 63 - 70, http://dx.doi.org/10.1016/j.euf.2019.04.020

2021, 'Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0)', Nature Genetics, 53, pp. 413, http://dx.doi.org/10.1038/s41588-021-00786-2

2021, 'Relationship between circulating lipids and cytokines in metastatic castration‐resistant prostate cancer', Cancers, 13, pp. 4964 - 4964, http://dx.doi.org/10.3390/cancers13194964

2021, 'Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction', Nature Genetics, 53, pp. 65 - 75, http://dx.doi.org/10.1038/s41588-020-00748-0

2021, 'Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer', Translational Andrology and Urology, 10, pp. 1688 - 1699, http://dx.doi.org/10.21037/tau-20-1444

2020, '1530P Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis', Annals of Oncology, 31, pp. S942 - S942, http://dx.doi.org/10.1016/j.annonc.2020.08.2013

2020, '1552P Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX', Annals of Oncology, 31, pp. S949 - S950, http://dx.doi.org/10.1016/j.annonc.2020.08.2035

2020, '5. Neurophysiological characteristics in the development and recovery of peripheral neuropathy in oxaliplatin and paxlitaxel treated patients', Clinical Neurophysiology, 131, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2019.11.038

2020, 'A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.', Journal of Clinical Oncology, 38, pp. e15125 - e15125, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e15125

2020, 'Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localized prostate cancer', Cancers, 12, http://dx.doi.org/10.3390/cancers12061385

2020, 'Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer', EBioMedicine, 54, http://dx.doi.org/10.1016/j.ebiom.2020.102728

2020, 'Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer', European Urology, 78, pp. 173 - 180, http://dx.doi.org/10.1016/j.eururo.2020.03.044

2020, 'Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis', bioRxiv, http://dx.doi.org/10.1101/2020.06.04.135277

2020, 'DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostate—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.', Journal of Clinical Oncology, 38, pp. TPS385 - TPS385, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps385

2020, 'Evaluation of a mainstream model of genetic testing for men with prostate cancer.', Journal of Clinical Oncology, 38, pp. 1521 - 1521, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.1521

2020, 'Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-020-14451-5

2020, 'Human decr1 is an androgen-repressed survival factor that regulates pufa oxidation to protect prostate tumor cells from ferroptosis', eLife, 9, pp. 1 - 34, http://dx.doi.org/10.7554/eLife.54166

2020, 'Inhibition of guanosine monophosphate synthetase (GMPS) blocks glutamine metabolism and prostate cancer growth in vitro and in vivo', , http://dx.doi.org/10.1101/2020.09.07.286997

2020, 'Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)', BMJ Open, 10, http://dx.doi.org/10.1136/bmjopen-2019-033667

2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 38, pp. TPS261 - TPS261, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.tps261

2020, 'Phase I, open-label, dose-escalation/ dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors', Journal of Clinical Oncology, 38, pp. 2140 - 2150, http://dx.doi.org/10.1200/JCO.19.02654

2020, 'Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors', Journal for ImmunoTherapy of Cancer, 8, http://dx.doi.org/10.1136/jitc-2019-000453

2020, 'Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients', Journal of Pain, 21, pp. 44 - 58, http://dx.doi.org/10.1016/j.jpain.2019.06.011

2019, 'A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)', Annals of Oncology, 30, pp. v353 - v353, http://dx.doi.org/10.1093/annonc/mdz248.052

2019, 'An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy', International Journal of Cancer, 144, pp. 1151 - 1159, http://dx.doi.org/10.1002/ijc.31906

2019, 'Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target', Neoplasia (United States), 21, pp. 389 - 400, http://dx.doi.org/10.1016/j.neo.2019.02.005

2019, 'Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8)', Nature Genetics, 51, pp. 363, http://dx.doi.org/10.1038/s41588-018-0330-6

2019, 'DNA Hypermethylation Encroachment at CpG Island Borders in Cancer Is Predisposed by H3K4 Monomethylation Patterns', Cancer Cell, 35, pp. 297 - 314.e8, http://dx.doi.org/10.1016/j.ccell.2019.01.004

2019, 'E6AP Promotes a Metastatic Phenotype in Prostate Cancer', iScience, 22, pp. 1 - 15, http://dx.doi.org/10.1016/j.isci.2019.10.065

2019, 'Enzalutamide with standard first-line therapy in metastatic prostate cancer', New England Journal of Medicine, 381, pp. 121 - 131, http://dx.doi.org/10.1056/NEJMoa1903835

2019, 'Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)', Nature Communications, 10, http://dx.doi.org/10.1038/s41467-019-08293-z

2019, 'Exceptional response to ¹⁷⁷lutetium prostate-specific membrane antigen in prostate cancer harboring DNA repair defects', JCO Precision Oncology, 3, pp. 1 - 5, http://dx.doi.org/10.1200/PO.18.00237

2019, 'Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 27, pp. 3849 - 3857, http://dx.doi.org/10.1007/s00520-019-04680-w

2019, 'Extracellular fatty acids are the major contributor to lipid synthesis in prostate cancer', Molecular Cancer Research, 17, pp. 949 - 962, http://dx.doi.org/10.1158/1541-7786.MCR-18-0347

2019, 'Flicking the switch off, targeting MCL-1 in the treatment of breast and prostate cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p038

2019, 'Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial', Annals of Oncology, 30, pp. v886 - v887, http://dx.doi.org/10.1093/annonc/mdz394.046

2019, 'Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone -sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial.', JOURNAL OF CLINICAL ONCOLOGY, 37, http://dx.doi.org/10.1200/JCO.2019.37.18_suppl.LBA2

2019, 'Rapid modulation of PSMA expression by androgen deprivation: Serial ⁶⁸Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade', Journal of Nuclear Medicine, 60, pp. 950 - 954, http://dx.doi.org/10.2967/jnumed.118.223099

2019, 'Results of a Prospective Phase 2 Pilot Trial of ¹⁷⁷ Lu–PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression', Clinical Genitourinary Cancer, 17, pp. 15 - 22, http://dx.doi.org/10.1016/j.clgc.2018.09.014

2019, 'Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial', European Urology, 76, pp. 306 - 312, http://dx.doi.org/10.1016/j.eururo.2018.11.001

2019, 'Statins – No more cream for cancer', European Journal of Cancer, 112, pp. 107 - 108, http://dx.doi.org/10.1016/j.ejca.2019.02.008

2019, 'Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours', Annals of Oncology, 30, pp. v166 - v167, http://dx.doi.org/10.1093/annonc/mdz244.013

2019, 'p53 nuclear accumulation as an early indicator of lethal prostate cancer', British Journal of Cancer, 121, pp. 578 - 583, http://dx.doi.org/10.1038/s41416-019-0549-8

Dadaev T; Saunders EJ; Newcombe PJ; Anokian E; Leongamornlert DA; Brook MN; Cieza-Borrella C; Mijuskovic M; Wakerell S; Olama AA A; Schumacher FR; Berndt SI; Benlloch S; Ahmed M; Goh C; Sheng X; Zhang Z; Muir K; Govindasami K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman P; Thompson IM; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger G; Gronberg H; Aly M; Nordström T; Pharoah P; Pashayan N; Schleutker J; Tammela TL J; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Hakansson N; West C; Dunning AM; Burnet N; Mucci L; Giovannucci E; Andriole G; Cussenot O; Cancel-Tassin G; Koutros S; Freeman LE B; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein B; Kerns S; Ostrer H; Lu YJ; Zhang HW; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; Fitzgerald LM; Kibel AS; Drake BF; Vega A; Gómez-Caamaño A; Fachal L; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castaño-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA, 2018, 'Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-04109-8

Kalsbeek AM F; Chan EK F; Grogan J; Petersen DC; Jaratlerdsiri W; Gupta R; Lyons RJ; Haynes AM; Horvath LG; Kench JG; Stricker PD; Hayes VM, 2018, 'Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer', Prostate, 78, pp. 25 - 31, http://dx.doi.org/10.1002/pros.23440

Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ, 2018, 'Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer', Prostate, 78, pp. 308 - 317, http://dx.doi.org/10.1002/pros.23476

Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A, 2018, 'MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-26050-y

Nair SS; Luu PL; Qu W; Maddugoda M; Huschtscha L; Reddel R; Chenevix-Trench G; Toso M; Kench JG; Horvath LG; Hayes VM; Stricker PD; Hughes TP; White DL; Rasko JE J; Wong JJ L; Clark SJ, 2018, 'Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten', Epigenetics and Chromatin, 11, http://dx.doi.org/10.1186/s13072-018-0194-0

Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM, 2018, 'Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants', Molecular and Cellular Proteomics, 17, pp. 1470 - 1486, http://dx.doi.org/10.1074/mcp.RA118.000633

Pidsley R; Lawrence MG; Zotenko E; Niranjan B; Statham A; Song J; Chabanon RM; Qu W; Wang H; Richards M; Nair SS; Armstrong NJ; Nim HT; Papargiris M; Balanathan P; French H; Peters T; Norden S; Ryan A; Pedersen J; Kench J; Daly RJ; Horvath LG; Stricker P; Frydenberg M; Taylor RA; Stirzaker C; Risbridger GP; Clark SJ, 2018, 'Enduring epigenetic landmarks define the cancer microenvironment', Genome Research, 28, pp. 625 - 638, http://dx.doi.org/10.1101/gr.229070.117

Roohullah A; Cooper A; Lomax AJ; Aung J; Barge A; Chow L; McHale M; Desai J; Whittle JR; Tran B; de Souza P; Horvath LG, 2018, 'A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers', Investigational New Drugs, 36, pp. 886 - 894, http://dx.doi.org/10.1007/s10637-018-0588-7

Schumacher FR; Al Olama AA; Berndt SI; Benlloch S; Ahmed M; Saunders EJ; Dadaev T; Leongamornlert D; Anokian E; Cieza-Borrella C; Goh C; Brook MN; Sheng X; Fachal L; Dennis J; Tyrer J; Muir K; Lophatananon A; Stevens VL; Gapstur SM; Carter BD; Tangen CM; Goodman PJ; Thompson IM; Batra J; Chambers S; Moya L; Clements J; Horvath L; Tilley W; Risbridger GP; Gronberg H; Aly M; Nordström T; Pharoah P; Pashayan N; Schleutker J; Tammela TL J; Sipeky C; Auvinen A; Albanes D; Weinstein S; Wolk A; Håkansson N; West CM L; Dunning AM; Burnet N; Mucci LA; Giovannucci E; Andriole GL; Cussenot O; Cancel-Tassin G; Koutros S; Beane Freeman LE; Sorensen KD; Orntoft TF; Borre M; Maehle L; Grindedal EM; Neal DE; Donovan JL; Hamdy FC; Martin RM; Travis RC; Key TJ; Hamilton RJ; Fleshner NE; Finelli A; Ingles SA; Stern MC; Rosenstein BS; Kerns SL; Ostrer H; Lu YJ; Zhang HW; Feng N; Mao X; Guo X; Wang G; Sun Z; Giles GG; Southey MC; MacInnis RJ; Fitzgerald LM; Kibel AS; Drake BF; Vega A; Gómez-Caamaño A; Szulkin R; Eklund M; Kogevinas M; Llorca J; Castaño-Vinyals G; Penney KL; Stampfer M; Park JY; Sellers TA; Lin HY; Stanford JL; Cybulski C, 2018, 'Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci', Nature Genetics, 50, pp. 928 - 936, http://dx.doi.org/10.1038/s41588-018-0142-8

Vafaee F; Diakos C; Kirschner MB; Reid G; Michael MZ; Horvath LG; Alinejad-Rokny H; Cheng ZJ; Kuncic Z; Clarke S, 2018, 'A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis', npj Systems Biology and Applications, 4, pp. 20 - 20, http://dx.doi.org/10.1038/s41540-018-0056-1

2018, '5. Neurophysiological dysfunction in chemotherapy-treated patients: Comparison of different platinum analogues', Clinical Neurophysiology, 129, pp. e2 - e3, http://dx.doi.org/10.1016/j.clinph.2017.12.018

2018, 'A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors', Annals of Oncology, 29, pp. x24 - x25, http://dx.doi.org/10.1093/annonc/mdy487.042

2018, 'Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer', New England Journal of Medicine, 378, pp. 1408 - 1418, http://dx.doi.org/10.1056/nejmoa1715546

2018, 'Germline variation at 8q24 and prostate cancer risk in men of European ancestry', Nature Communications, 9, http://dx.doi.org/10.1038/s41467-018-06863-1

Barnet MB; O'Toole S; Horvath LG; Selinger C; Yu B; Ng CC; Boyer M; Cooper WA; Kao S, 2017, 'EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors', Journal of Thoracic Oncology, 12, pp. 585 - 590, http://dx.doi.org/10.1016/j.jtho.2016.09.001

Grogan J; Gupta R; Mahon KL; Stricker PD; Haynes AM; Delprado W; Turner J; Horvath LG; Kench JG, 2017, 'Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up', BJU International, 120, pp. 651 - 658, http://dx.doi.org/10.1111/bju.13857

Kandula T; Farrar MA; Kiernan MC; Krishnan AV; Goldstein D; Horvath L; Grimison P; Boyle F; Baron-Hay S; Park SB, 2017, 'Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer', Clinical Neurophysiology, 128, pp. 1166 - 1175, http://dx.doi.org/10.1016/j.clinph.2017.04.009

Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG, 2017, 'Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer', British Journal of Cancer, 116, pp. 1002 - 1011, http://dx.doi.org/10.1038/bjc.2017.50

Lin HM; Mahon KL; Weir JM; Mundra PA; Spielman C; Briscoe K; Gurney H; Mallesara G; Marx G; Stockler MR; Prime C; Parton RG; Hoy AJ; Daly RJ; Meikle PJ; Horvath LG, 2017, 'A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer', International Journal of Cancer, 141, pp. 2112 - 2120, http://dx.doi.org/10.1002/ijc.30903

McCrary JM; Goldstein D; Boyle F; Cox K; Grimison P; Kiernan MC; Krishnan AV; Lewis CR; Webber K; Baron-Hay S; Horvath L; Park SB, 2017, 'Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey', Supportive Care in Cancer, 25, pp. 3485 - 3493, http://dx.doi.org/10.1007/s00520-017-3772-y

Nikolic I; Elsworth B; Dodson E; Wu SZ; Gould CM; Mestdagh P; Marshall GM; Horvath LG; Simpson KJ; Swarbrick A, 2017, 'Discovering cancer vulnerabilities using high-throughput micro-RNA screening', Nucleic Acids Research, 45, pp. 12657 - 12670, http://dx.doi.org/10.1093/nar/gkx1072

Quinn DI; Sandler HM; Horvath LG; Goldkorn A; Eastham JA, 2017, 'The evolution of chemotherapy for the treatment of prostate cancer', Annals of Oncology, 28, pp. 2658 - 2669, http://dx.doi.org/10.1093/annonc/mdx348

Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR J; O'Toole SA; Cooper WA, 2017, 'Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target', Histopathology, 70, pp. 402 - 411, http://dx.doi.org/10.1111/his.13076

Valdés-Mora F; Gould CM; Colino-Sanguino Y; Qu W; Song JZ; Taylor KM; Buske FA; Statham AL; Nair SS; Armstrong NJ; Kench JG; Lee KM L; Horvath LG; Qiu M; Ilinykh A; Yeo-Teh NS; Gallego-Ortega D; Stirzaker C; Clark SJ, 2017, 'Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer', Nature Communications, 8, http://dx.doi.org/10.1038/s41467-017-01393-8

Zhang AY; Grogan JS; Mahon KL; Rasiah K; Sved P; Eisinger DR; Boulas J; Vasilaris A; Henshall SM; Stricker PD; Kench JG; Horvath LG, 2017, 'A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer', Annals of Oncology, 28, pp. 1903 - 1909, http://dx.doi.org/10.1093/annonc/mdx247

2017, 'MP83-01 HIGH-GRADE PROSTATE CANCER HAS INCREASED MITOCHONDRIAL CONTENT', Journal of Urology, 197, http://dx.doi.org/10.1016/j.juro.2017.02.2569

2017, 'Mitochondrial genome content is decreased in prostate cancer overall, but increased in high grade cancer', Pathology, 49, pp. S104 - S105, http://dx.doi.org/10.1016/j.pathol.2016.12.300

2017, 'Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel (DTX) in metastatic castration resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 35, pp. 5014 - 5014, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5014

2017, 'Preliminary results from a subset of patients (pts) with advanced head and neck squamous carcinoma (HNSCC) in a dose-escalation and dose-expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v129 - v130, http://dx.doi.org/10.1093/annonc/mdx367.022

2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023

Bonilla C; Lewis SJ; Martin RM; Donovan JL; Hamdy FC; Neal DE; Eeles R; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Pashayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park J; Kaneva R; Batra J; Teixeira MR; Pandha H; Lathrop M; Smith GD; Cook M; Morga A; Lophatananon A; Fisher C; Leongamornlert D; Saunders EJ; Sawyer EJ; Govindasami K; Tymrakiewicz M; Guy M; Livni N; Wilkinson R; Jugurnauth-Little S; Hazel S; Dadaev T; Southey MC; Fitzgerald LM; Pedersen J; Hopper J; Karlsson A; Cavalli-Bjoerkman C; Johansson JE; Adolfson J; Aly M; Broms M; Stattin P; Henderson BE; Schumacher F; Auvinen A; Taari K; Maeaettaenen L; Kujala P; Murtola T; Tammela TL J; Sipeky C; Roder MA; Iversen P; Klarskov P; Nielsen SF; Weischer M; Key TJ; Wallinder H; Gustafsson S; Cox A; George A; Lane A; Marsden G; Davis M; Brown P; Pharoah P; Signorello LB; Zheng W; McDonnell SK; Schaid DJ; Wang L; Tillmans L; Riska S; Schnoeller T; Herkommer K; Luedeke M; Vogel W; Wokozorczyk D; Lubiski J; Kluzniak W, 2016, 'Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort', BMC Medicine, 14, http://dx.doi.org/10.1186/s12916-016-0602-x

Bruce HM; Stricker PD; Gupta R; Savdie RR; Haynes AM; Mahon KL; Lin HM; Kench JG; Horvath LG, 2016, 'Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer', Prostate, 76, pp. 1491 - 1500, http://dx.doi.org/10.1002/pros.23233

Fromm PD; Papadimitrious MS; Hsu JL; Van Kooten Losio N; Verma ND; Lo TH; Silveira PA; Bryant CE; Turtle CJ; Prue RL; Vukovic P; Munster DJ; Nagasaki T; Barnard RT; Mahler SM; Anguille SA; Berneman Z; Horvath LG; Bradstock KF; Joshua DE; Clark GJ; Hart DN J, 2016, 'CMRF-56⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses', OncoImmunology, 5, http://dx.doi.org/10.1080/2162402X.2016.1168555

Humphrey ES; Su SP; Nagrial AM; Hochgrä Fe F; Pajic M; Lehrbach GM; Parton RG; Yap AS; Horvath LG; Chang DK; Biankin AV; Wu J; Daly RJ, 2016, 'Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling', Molecular and Cellular Proteomics, 15, pp. 2671 - 2685, http://dx.doi.org/10.1074/mcp.M116.058313

Kalsbeek AM F; Chan EF K; Grogan J; Petersen DC; Jaratlerdsiri W; Gupta R; Lyons RJ; Haynes AM; Horvath LG; Kench JG; Stricker PD; Hayes VM, 2016, 'Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer', Aging, 8, pp. 2702 - 2712, http://dx.doi.org/10.18632/aging.101044

Lomax AJ; Beith J; Bhadri V; Boyer M; Grimison P; Horvath LG; Kao S; Tattersall M; Thomas D; McNeil C, 2016, 'Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse', Internal Medicine Journal, 46, pp. 1392 - 1398, http://dx.doi.org/10.1111/imj.13232

2016, 'Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).', Journal of Clinical Oncology, 34, pp. 5039 - 5039, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.5039

2016, 'mRNA Loaded CMRF-56 Blood Dendritic Cells Augment Anti-Cancer Immune Responses in Conjunction with Nivolumab', Cytotherapy, 18, pp. S100 - S100, http://dx.doi.org/10.1016/j.jcyt.2016.03.205

Gupta R; O'Connell R; Haynes A-M; Stricker PD; Barrett W; Turner JJ; Delprado W; Horvath LG; Kench JG, 2015, 'Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?', BJU International, 116, pp. n/a - n/a, http://dx.doi.org/10.1111/bju.12911

Mahon KL; Lin HM; Castillo L; Lee BY; Lee-Ng M; Chatfield MD; Chiam K; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Daly RJ; Henshall SM; Horvath LG, 2015, 'Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer', British Journal of Cancer, 112, pp. 1340 - 1348, http://dx.doi.org/10.1038/bjc.2015.74

Rynkiewicz NK; Fedele CG; Chiam K; Gupta R; Kench JG; Ooms LM; McLean CA; Giles GG; Horvath LG; Mitchell CA, 2015, 'INPP4Bis highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival', Prostate, 75, pp. 92 - 102, http://dx.doi.org/10.1002/pros.22895

Stegeman S; Amankwah E; Klein K; O’Mara TA; Kim D; Lin HY; Permuth-Wey J; Sellers TA; Srinivasan S; Eeles R; Easton D; Kote-Jarai Z; Al Olama AA; Benlloch S; Muir K; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pharoah P; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Kaneva R; Teixeira MR; Spurdle AB; Clements JA; Park JY; Batra J; Cook M; Morgan A; Lophatananon A; Fisher C; Leongamornlert D; Saunders EJ; Sawyer EJ; Govindasami K; Tymrakiewicz M; Guy M; Livni N; Wilkinson R; Jugurnauth-Little S; Hazel S; Dadaev T; Pedersen J; Hopper JL; Southey MC; Karlsson A; Cavalli-Bjoerkman C; Johansson JE; Adolfson J; Aly M; Broms M; Stattin P; Henderson BE; Schumacher F; Auvinen A; Taari K; Maeaettaenen L; Kujala P; Murtola T; Tammela TL J; Wahlfors T; Roder A; Iversen P; Klarskov P; Nielsen SF; Weischer M; Key TJ; Wallinder H; Gustafsson S; Donovan JL; Hamdy F; George A; Lane A; Marsden G; Davis M; Brown P; Pashayan N; Holt S; Signorello LB; Zheng W; Wang L; Tillmans L; Riska S; Rinckleb A; Herkommer K; Luedeke M, 2015, 'A large-scale analysis of genetic variants within putative miRNA binding sites in prostate cancer', Cancer Discovery, 5, pp. 368 - 379, http://dx.doi.org/10.1158/2159-8290.CD-14-1057

Yates A; Carroll S; Kneebone A; Tse R; Horvath L; Byrne C; Solomon M; Hruby G, 2015, 'Implementing intensity-modulated radiotherapy with simultaneous integrated boost for anal cancer: 3 year outcomes at two Sydney institutions', Clinical Oncology, 27, pp. 700 - 707, http://dx.doi.org/10.1016/j.clon.2015.08.006

2015, 'FAK signaling in human cancer as a target for therapeutics', Pharmacology & therapeutics, 146, pp. 132 - 149, http://dx.doi.org/10.1016/j.pharmthera.2014.10.001

2015, 'PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma', Lung Cancer, 89, pp. 181 - 188, http://dx.doi.org/10.1016/j.lungcan.2015.05.007

2015, 'Prediction of Individual Genetic Risk to Prostate Cancer Using a Polygenic Score', PROSTATE, 75, pp. 1467 - 1474, http://dx.doi.org/10.1002/pros.23037

2015, 'Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials', Critical Reviews in Oncology/Hematology, 96, pp. 483 - 497, http://dx.doi.org/10.1016/j.critrevonc.2015.07.007

Birch SE; Kench JG; Takano E; Chan P; Chan A-L; Chiam K; Veillard A-S; Stricker P; Haupt S; Haupt Y; Horvath L; Fox SB, 2014, 'Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death', Annals of Oncology, 25, pp. 2392 - 2397, http://dx.doi.org/10.1093/annonc/mdu454

Cooper WA; Selinger CI; Tran TN; Pavlakis N; Yip PY; Horvath L; Kohonen-Corish MR; O'Toole S, 2014, '11. Ros1 gene rearrangements in non-small cell lung carcinoma - a new genetic target.', Pathology, 46 Suppl 1, pp. S110, http://dx.doi.org/10.1097/01.PAT.0000443701.27695.95

Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; Macdonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS, 2014, 'ERG induces taxane resistance in castration-resistant prostate cancer', Nature Communications, 5, http://dx.doi.org/10.1038/ncomms6548

Nagrial AM; Chang DK; Nguyen NQ; Johns AL; Chantrill LA; Humphris JL; Chin VT; Samra JS; Gill AJ; Pajic M; Pinese M; Colvin EK; Scarlett CJ; Chou A; Kench JG; Sutherland RL; Horvath LG; Biankin AV, 2014, 'Adjuvant chemotherapy in elderly patients with pancreatic cancer', British Journal of Cancer, 110, pp. 313 - 319, http://dx.doi.org/10.1038/bjc.2013.722

Sutherland SI M; Pe Benito R; Henshall SM; Horvath LG; Kench JG, 2014, 'Expression of phosphorylated-mTOR during the development of prostate cancer', Prostate, 74, pp. 1231 - 1239, http://dx.doi.org/10.1002/pros.22840

Suttie CF; Hruby G; Horvath L; Thompson J, 2014, 'Cardiac metastasis in Merkel cell carcinoma', Journal of Clinical Oncology, 32, http://dx.doi.org/10.1200/JCO.2012.48.3073

2014, 'Anzup 1302 P3Bep Companion Translational Study: Prospective Collection of Whole Blood, Serum, Plasma and Tumour Tissue in a Randomized Trial of Chemotherapy for Metastatic Germ Cell Tumours (Gct)', Annals of Oncology, 25, pp. iv304 - iv304, http://dx.doi.org/10.1093/annonc/mdu337.67

2014, 'Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer', British Journal of Cancer, 110, pp. 2462 - 2471, http://dx.doi.org/10.1038/bjc.2014.181

2014, 'Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer', British Journal of Cancer, 111, pp. 1802 - 1809, http://dx.doi.org/10.1038/bjc.2014.463

2014, 'Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer', Journal of Clinical Pathology, 67, pp. 333 - 340, http://dx.doi.org/10.1136/jclinpath-2013-201870

Cooper WA; Selinger CI; Tran TN; Pavlakis N; Yip PY; Horvath LG; Kohonen-Corish M; O'Toole S, 2013, 'ROS1 GENE REARRANGEMENTS IN NON-MALL CELL LUNG CARCINOMA - A NEW GENETIC TARGET THAT CAN BE IDENTIFIED BY IMMUNOHISTOCHEMISTRY AND FISH', JOURNAL OF THORACIC ONCOLOGY, 8, pp. S1251 - S1251, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624906085&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR J; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA, 2013, 'EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma', Journal of Clinical Pathology, 66, pp. 744 - 748, http://dx.doi.org/10.1136/jclinpath-2013-201607

Lee BY; Hochgraefe F; Lin H-M; Castillo L; Wu J; Raftery M; Shreeve SM; Horvath L; Daly R, 2013, 'Focal adhesion kinase: a mediator of docetaxel-resistance in castrate resistant prostate cancer', BJU INTERNATIONAL, 112, pp. 38 - 39, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100100&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ, 2013, 'Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer', Molecular Cancer Therapeutics, 13, pp. 190 - 201, http://dx.doi.org/10.1158/1535-7163.MCT-13-0225-T

Selth L; Townley S; Bert A; Stricker P; Sutherland P; Horvath L; Goodall G; Butler L; Tilley W, 2013, 'CIRCULATING microRNAs PREDICT BIOCHEMICAL RECURRENCE IN PROSTATE CANCER PATIENTS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 63 - 63, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sutherland S; Henshall S; Horvath L; Kench J, 2013, 'THE ROLE OF MAMMALIAN TARGET OF RAPAMYCIN (mTOR) IN THE DEVELOPMENT OF PROSTATE CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 9, pp. 49 - 50, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000329462300016&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip PY; Cooper WA; Kohonen-Corish M; Mccaughan B; Boyer M; Kench J; Horvath LG, 2013, 'PHOSPHORYLATED-AKT EXPRESSION IS A PROGNOSTIC MARKER IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)', JOURNAL OF THORACIC ONCOLOGY, 8, pp. S785 - S785, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624903324&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yu B; Mercorella B; Irwin D; Ng CC; Hunt P; Yip PY; Kohonen-Corish M; Horvath LG; Cooper WA; Trent RJ; O'Toole S, 2013, 'SIMULTANEOUS PROFILING OF MULTIGENE MUTATIONS FOR THE EFFECTIVE AND EFFICIENT DIAGNOSIS OF NON-SMALL CELL LUNG CARCINOMA', JOURNAL OF THORACIC ONCOLOGY, 8, pp. S784 - S785, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624903322&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2013, 'Abiraterone in metastatic prostate cancer without previous chemotherapy', New England Journal of Medicine, 368, pp. 138 - 148, http://dx.doi.org/10.1056/NEJMoa1209096

2013, 'Circulating microRNAs predict biochemical recurrence in prostate cancer patients.', British Journal of Cancer, 109, pp. 641 - 650, http://dx.doi.org/10.1038/bjc.2013.369

2013, 'Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy', EUROPEAN JOURNAL OF CANCER, 49, pp. 3648 - 3657, http://dx.doi.org/10.1016/j.ejca.2013.07.144

2013, 'Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer', Oncogene, 32, pp. 2891 - 2899, http://dx.doi.org/10.1038/onc.2012.300

2013, 'Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma', Journal of Thoracic Oncology, 8, pp. 408 - 414, http://dx.doi.org/10.1097/JTO.0b013e318283558e

2013, 'Testing for ALK rearrangement in lung adenocarcinoma: A multicenter comparison of immunohistochemistry and fluorescent in situ hybridization', Modern Pathology, 26, pp. 1545 - 1553, http://dx.doi.org/10.1038/modpathol.2013.87

2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 31, pp. e22175 - e22175, http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e22175

Chua W; Horvath L; Beale P; Clarke SJ, 2012, 'Reporting clinical trial information: Colorectal cancer trials at Sydney Cancer Centre', Internal Medicine Journal, 42, pp. 416 - 421, http://dx.doi.org/10.1111/j.1445-5994.2011.02441.x

Cooper WA; Yu B; Yip PY; Farzin M; Clarkson A; Kohonen-Corish MJ; Horvath L; Kench JG; McCaughan B; O'Toole SA; Gill AJ, 2012, 'EGFR MUTANT SPECIFIC IMMUNOHISTOCHEMISTRY HAS HIGH SPECIFICITY BUT ONLY MODERATE SENSITIVITY FOR DETECTING COMMON ACTIVATING EGFR MUTATIONS IN LUNG ADENOCARCINOMA', JOURNAL OF THORACIC ONCOLOGY, 7, pp. S162 - S162, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900018&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Femia G; Hardy TA; Spies JM; Horvath LG, 2012, 'Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: A case report and literature review', Asia-Pacific Journal of Clinical Oncology, 8, pp. 115 - 122, http://dx.doi.org/10.1111/j.1743-7563.2012.01544.x

Randall SA; Mckay MJ; Pascovici D; Mahon K; Horvath L; Clarke SJ; Molloy MP, 2012, 'Remarkable temporal stability of high-abundance human plasma proteins assessed by targeted mass spectrometry', Proteomics - Clinical Applications, 6, pp. 626 - 634, http://dx.doi.org/10.1002/prca.201200039

Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG, 2012, 'High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy', BJU International, 109, pp. 1794 - 1800, http://dx.doi.org/10.1111/j.1464-410X.2011.10572.x

Selinger C; Rogers T; Russell P; Yip P; O'Toole S; Horvath L; Boyer M; McCaughan B; Kohonen-Corish M; Fox S; Cooper W; Solomon B, 2012, 'ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGEMENT IN LUNG ADENOCARCINOMAS - A LARGE MULTICENTRE STUDY OF FISH AND IHC.', JOURNAL OF THORACIC ONCOLOGY, 7, pp. S182 - S182, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900086&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Venkateswaran LP; Butow PN; Jansen J; Wilcken NR C; Wong MK; Hui R; Szonyi G; Gebski VJ; Naganathan V; Horvath LG; Tattersall MH N, 2012, 'Decision making in older patients with advanced cancer: Does doctor know best?', Medical Journal of Australia, 196, pp. 35 - 39, http://dx.doi.org/10.5694/mja11.10907

Yip PY; Yu B; Cooper WA; Kench JG; Boyer M; Kohonen-Corish MJ; Trent R; McCaughan B; Kennedy C; O'Toole SA; Horvath L, 2012, 'MUTATIONS IN RESECTED NODE-NEGATIVE LUNG ADENOCARCINOMA', JOURNAL OF THORACIC ONCOLOGY, 7, pp. S189 - S190, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000317034900113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2012, 'Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study', LANCET ONCOLOGY, 13, pp. 983 - 992, http://dx.doi.org/10.1016/S1470-2045(12)70379-0

2012, 'Abstract A33: Characterization of signaling pathways associated with docetaxel resistance in prostate cancer', Cancer Research, 72, pp. A33 - A33, http://dx.doi.org/10.1158/1538-7445.prca2012-a33

2012, 'Patterns of somatic mutations in an Australian cohort of lung adenocarcinoma', Pathology, 44, pp. S90 - S90, http://dx.doi.org/10.1016/s0031-3025(16)32856-2

2012, 'Testing for anaplastic lymphoma kinase (ALK) rearrangement in lung adenocarcinomas: a multicentre study', Pathology, 44, pp. S95 - S95, http://dx.doi.org/10.1016/s0031-3025(16)32872-0

2012, 'The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer', British Journal of Cancer, 106, pp. 61 - 69, http://dx.doi.org/10.1038/bjc.2011.526

Horvath L; Mahon KL; Qu W; Devaney J; Chatfield MD; Paul C; Wykes R; Boyer MJ; Stockler MR; Marx GM; Sutherland RL; Clark SJ, 2011, 'A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC).', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4603

Kench JG; Clouston DR; Delprado W; Eade T; Ellis D; Horvath LG; Samaratunga H; Stahl J; Stapleton AM F; Egevad L; Srigley JR; Delahunt B, 2011, 'Prognostic factors in prostate cancer. Key elements in structured histopathology reporting of radical prostatectomy specimens', Pathology, 43, pp. 410 - 419, http://dx.doi.org/10.1097/PAT.0b013e328348a6b3

Savdie R; Horvath L; Pebenito R; Rasiah K; Haynes AM; Stricker P; Turner J; Delprado W; Henshall S; Sutherland R; Kench J, 2011, 'High Gleason grade carcinoma at a positive margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy', BJU INTERNATIONAL, 107, pp. 20 - 21, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000286596800047&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yip PY; Cooper W; Mahar A; Kench J; Kohonen-Corish MR J; Chatfield M; Boulghourjian A; Kennedy CW; Mccaughan B; Boyer M; Horvath L, 2011, 'MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC)', JOURNAL OF THORACIC ONCOLOGY, 6, pp. S499 - S499, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208855802235&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2011, 'Abiraterone and Increased Survival in Metastatic Prostate Cancer', NEW ENGLAND JOURNAL OF MEDICINE, 364, pp. 1995 - 2005, http://dx.doi.org/10.1056/NEJMoa1014618

2011, 'Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC).', JOURNAL OF CLINICAL ONCOLOGY, 29, http://dx.doi.org/10.1200/jco.2011.29.15_suppl.4598

2011, 'Epigenetic deregulation across chromosome 2q14.2 differentiates normal from prostate cancer and provides a regional panel of novel DNA methylation cancer biomarkers', Cancer Epidemiology Biomarkers and Prevention, 20, pp. 148 - 159, http://dx.doi.org/10.1158/1055-9965.EPI-10-0719

2011, 'Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer', Prostate, 71, pp. 1638 - 1645, http://dx.doi.org/10.1002/pros.21381

2011, 'Pathways of chemotherapy resistance in castration-resistant prostate cancer', Endocrine - Related Cancer, 18, pp. 103 - 123, http://dx.doi.org/10.1530/ERC-10-0343

2011, 'Supporting treatment decision-making in advanced cancer: a randomized trial of a decision aid for patients considering chemotherapy in advanced colorectal cancer', Journal of Clinical Oncology, 29, pp. 2077 - 2084, http://dx.doi.org/10.1200/JCO.2010.32.0754

2011, 'What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements', Pathology, 43, pp. 103 - 115, http://dx.doi.org/10.1097/PAT.0b013e28342629d

Lubner SJ; Mahoney MR; Kolesar JL; LoConte NK; Kim GP; Pitot HC; Philip PA; Picus J; Yong WP; Horvath L; Van Hazel G; Erlichman CE; Holen KD, 2010, 'Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A phase II consortium study', Journal of Clinical Oncology, 28, pp. 3491 - 3497, http://dx.doi.org/10.1200/JCO.2010.28.4075

Nagrial A; Horvath L, 2010, 'Bone disease in prostate cancer', Asia-Pacific Journal of Clinical Oncology, 6, pp. 3 - 4, http://dx.doi.org/10.1111/j.1743-7563.2010.01281.x

Ocean AJ; Polite B; Christos P; Horvath L; Hamilton A; Matulich D; Chen HX; Sparano JA; Kindler HL, 2010, 'Cetuximab is associated with excessive toxicity when combined with bevacizumab plus mFOLFOX6 in metastatic colorectal carcinoma', Clinical Colorectal Cancer, 9, pp. 290 - 296, http://dx.doi.org/10.3816/CCC.2010.n.042

Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; Van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ; Price T; Coates A; O'Connell D; Brown C; Hague W; France A; Hicks S; James R; Masson R; O'Connell R; Pike R; Shoulder J; Stevens L; Tunney V; Vachan B; Wong N; Ackland S; Moylan E; Strickland A; Abdi E; Ransom D; Lowenthal R; Marx G; Nayagam SS; Shannon J; Goldstein D; Karapetis C; Blum R; Eek R; Ward R; Pavlakis N; Wilcken N; Burns I; Wyld D; Underhill C; Claringbold P; Liauw W; Clingan P; Jefford M; Horvath L; McKendrick J; Chong G; Boyce A; Cassidy J; Kirsten F; Clarke S; Guo Y; Innes-Rowe J; Smith A; Williams J; Tournier E; Maliepaard S; Vitullo E; Humm G; Nguyen V; Midolo P; Chorlton C; McDonald L; Oliver L; Sjursen AM; Inglis C; Marafioti T; McCourt J; Howard J; Richards A; Provis A; Rundle A; Whatman A; Emmett L; Raymond B; Byrne S; Withers E; Campbell J; Hodgkins C; Szwajcer M; Parker S; Welby S; Page F; Corker M; Wykes R; Goss C; Whitney S, 2010, 'Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study', Journal of Clinical Oncology, 28, pp. 3191 - 3198, http://dx.doi.org/10.1200/JCO.2009.27.7723

Yip P; Kench J; Rasiah K; Benito R; Lee C; Henshall S; Sutherland R; Horvath L, 2010, 'Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer', JOURNAL OF CLINICAL ONCOLOGY, 28, http://dx.doi.org/10.1200/jco.2010.28.15_suppl.4650

2010, '300 CAN THE GLEASON GRADE AT THE SITE OF A POSITIVE MARGIN PREDICT BIOCHEMICAL FAILURE POST RADICAL PROSTATECTOMY?', Journal of Urology, 183, http://dx.doi.org/10.1016/j.juro.2010.02.363

2010, 'Stage migration in localized prostate cancer has no effect on the post-radical prostatectomy Kattan nomogram', BJU International, 10, pp. 642 - 647, http://dx.doi.org/10.1111/j.1464-410X.2009.08842.x

Horvath L; Zhao L; Lee B; Brown D; Molloy M; Marx G; Boyer M; Breit S; Sutherland R; Henshall S, 2009, 'Identification of candidate biomarkers of therapeutic response to docetaxel in hormone-refractory prostate cancer by proteomic profiling.', J Clin Oncol, 27, pp. 11010, http://www.ncbi.nlm.nih.gov/pubmed/27963974

Karim RZ; Gerega SK; Yang YH; Horvath L; Spillane A; Carmalt H; Scolyer RA; Lee CS, 2009, 'Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours', Journal of Clinical Pathology, 62, pp. 1016 - 1020, http://dx.doi.org/10.1136/jcp.2009.066977

Moore MM; Chua W; Zhao J; Clarke SJ; Horvath L, 2009, 'Evaluation of plasma total and cleaved cytokeratin 18 as predictive markers of chemotherapy in colorectal cancer.', J Clin Oncol, 27, pp. e15091, http://www.ncbi.nlm.nih.gov/pubmed/27964608

Tattersall MH N; Dear RF; Jansen J; Shepherd HL; Devine RJ; Horvath LG; Boyer ML, 2009, 'Second opinions in oncology: the experiences of patients attending the Sydney Cancer Centre', Medical Journal of Australia, 191, pp. 209 - 212, http://www.mja.com.au/public/issues/191_04_170809/tat10235_fm.pdf

2009, 'Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer', British Journal of Cancer, 100, pp. 1784 - 1793, http://dx.doi.org/10.1038/sj.bjc.6605089

2009, 'Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling', Cancer research, 69, pp. 7696 - 7703, http://dx.doi.org/10.1158/0008-5472.CAN-08-4901

2009, 'Proteins from the wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours', Pathology, 41, pp. 60 - 61, http://dx.doi.org/10.1097/01268031-200941001-00132

2009, 'Synoptic reporting improves histopathological assessment of pancreatic resection specimens', Pathology, 41, pp. 161 - 167, http://dx.doi.org/10.1080/00313020802337329

2009, 'Targeted plasma proteome profiling for early prediction of chemotherapy response and toxicity in colorectal cancer (CRC)', Journal of Clinical Oncology, 27, pp. e15063 - e15063, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e15063

Horvath L; Thanigasalam R; Rasiah K; Stricker P; Earnest A; Haynes A; Sutherland S; Sutherland R; Henshall S, 2008, 'Stage migration and the Kattan nomogram', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5162

2008, 'Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer', Prostate, 68, pp. 1421 - 1429, http://dx.doi.org/10.1002/pros.20809

2008, 'DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma', British Journal of Cancer, 99, pp. 375 - 382, http://dx.doi.org/10.1038/sj.bjc.6604452

2008, 'Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse', Cancer epidemiology biomarkers and prevention, 17, pp. 2488 - 2497, http://dx.doi.org/10.1158/1055-9965.EPI-08-0204

2008, 'Improving outcomes for operable pancreatic cancer: is access to safer surgery the problem?', Journal of Gastroenterology and Hepatology, 23, pp. 1036 - 1045, http://dx.doi.org/10.1111/j.1440-1746.2008.05471.x

2008, 'Temporal associations with declining Trichomonas vaginalis diagnosis rates among women in the state of Victoria, Australia, 1947 to 2005', Sexually Transmitted Diseases, 35, pp. 572 - 576, http://dx.doi.org/10.1097/OLQ.0b013e3181666aa3

2007, 'MP-11.18: Is there evidence of a continued stage migration in the PSA screening era in an Australian population?', Urology, 70, pp. 99 - 100, http://dx.doi.org/10.1016/j.urology.2007.06.401

2007, 'Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer', Prostate, 64 (1), pp. 1081 - 1090, http://dx.doi.org/10.1002/pros.20607

Henshall SM; Horvath LG; Quinn DI; Eggleton SA; Grygiel JJ; Stricker PD; Biankin AV; Kench JG; Sutherland RL, 2006, 'Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy', Journal of the National Cancer Institute, 98, pp. 1420 - 1424, http://dx.doi.org/10.1093/jnci/djj378

Sharma R; Rivory L; Beale P; Ong S; Horvath L; Clarke SJ, 2006, 'A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer', British Journal of Cancer, 94, pp. 964 - 968, http://dx.doi.org/10.1038/sj.bjc.6603049

2006, 'Aberrant neuropepticle Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis', Cancer epidemiology biomarkers and prevention, 15, pp. 711 - 716, http://dx.doi.org/10.1158/1055-9965.EPI-05-0752

2006, 'Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer', EJC Supplements, 4, pp. 120 - 120, http://dx.doi.org/10.1016/S1359-6349(06)70395-0

Zeng Y; Opeskin K; Baldwin ME; Horvath LG; Achen MG; Stacker SA; Sutherland RL; Williams ED; Loberg RD; Pienta KJ, 2005, 'Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer', Urologic Oncology: Seminars and Original Investigations, 23, pp. 76, http://dx.doi.org/10.1016/j.urolonc.2004.11.005

2005, 'Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI- a pilot study', Journal of Clinical Oncology, 23, pp. 8243 - 8243, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.8243

2005, 'Lower levels of nuclear b-catenin predict for a poorer prognosis in localised prostate cancer', International Journal of Cancer, 113, pp. 415 - 422, http://dx.doi.org/10.1002/ijc.20599

2005, 'Lymphatic vessel density and lymph node metastasis in prostate cancer', Prostate, 65, pp. 222 - 230, http://dx.doi.org/10.1002/pros.20288

Horvath LG; Henshall SM; Lee CS; Kench JG; Stricker PD; Grygiel JJ; Sutherland RL, 2004, 'Nuclear beta-catenin as a marker of outcome in localized prostate cancer', Journal of Clinical Oncology, 22, pp. 852S - 852S, http://www.ncbi.nlm.nih.gov/pubmed/28016659

2004, '1079: Neuropeptide Y Expression is increased in the Progression from Benign to Malignant Prostate Epithelium and Predicts Outcome after Radical Prostatectomy', Journal of Urology, 171, pp. 284 - 285, http://dx.doi.org/10.1016/s0022-5347(18)38316-2

2004, 'Expression of vascular endothelial growth factor receptor-3 bylymphatic endothelial cells is associated with lymph node metastasis inprostate cancer', Clinical Cancer Research, 10, pp. 5137 - 5144, http://dx.doi.org/10.1158/1078-0432.CCR-03-0434

2004, 'Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression', Prostate, 59, pp. 234 - 242, http://dx.doi.org/10.1002/pros.10361

2004, 'Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro', Clinical Cancer Research, 10, pp. 615 - 625, http://dx.doi.org/10.1158/1078-0432.CCR-0707-03

2004, 'Nuclear beta-catenin as a marker of outcome in localized prostate cancer', Journal of Clinical Oncology, 22, pp. 9570 - 9570, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.9570

2004, 'Nuclear beta-catenin as a marker of outcome in localized prostate cancer', Journal of Clinical Oncology, 22, pp. 9570 - 9570, http://dx.doi.org/10.1200/jco.2004.22.90140.9570

2003, 'Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease ot invasive prostate cancer', Oncogene, 22, pp. 6005 - 6012, http://dx.doi.org/10.1038/sj.onc.1206797

2003, 'Survival analaysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse', Cancer research, 63, pp. 4196 - 4203

Horvath LG; McCaughan BC; Stockler M; Boyer MJ, 2002, 'Resection of residual pulmonary masses after chemotherapy in patients with metastatic non-seminomatous germ cell tumours', Internal Medicine Journal, 32, pp. 79 - 83, http://dx.doi.org/10.1046/j.1445-5994.2002.00169.x

Afar D; Henshall S; Gish K; Horvath L; Head D; Sutherland R; Mack D, 2001, 'Identification of immunotherapeutic targets in prostate cancer by genome-wide molecular profiling.', CLINICAL CANCER RESEARCH, 7, pp. 3692S - 3692S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172121800192&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Horvath L; Bayfield M; Clifford A; Painter D; Clarke S, 2001, 'Case 1. Recurrent laryngeal nerve palsy in mediastinal seminoma', Journal of Clinical Oncology, 19, pp. 909 - 911, http://dx.doi.org/10.1200/jco.2001.19.3.909

Horvath L; Boyer M; Clarke S; Beale P; Beith J; Underhill C; Stockler M; Bishop J, 2001, 'Carboplatin and vinorelbine in untreated locally advanced and metastatic non-small cell lung cancer', Lung Cancer, 32, pp. 173 - 178, http://dx.doi.org/10.1016/S0169-5002(00)00218-X

Horvath L; Henshall S, 2001, 'Timely topic: The application of tissue microarrays to cancer research', Pathology, 33, pp. 125 - 129, http://dx.doi.org/10.1080/003130201200338791

Horvath L; McDowell D; Stevens G; Parkinson R; McCarthy S; Boyer M, 2001, 'Case 2. Seminoma of the conus medullaris', Journal of Clinical Oncology, 19, pp. 911 - 915, http://dx.doi.org/10.1200/jco.2001.19.3.911

2001, 'The application of tissue microarrays to cancer research', PATHOLOGY, 33, pp. 125 - 129, http://dx.doi.org/10.1080/003130201200338791

PATER J; KERDO I; SEBESTYEN L; HORVATH L, 1957, 'Complex examinations on industrial hygiene in the workshops of the Hungarian Railways.', Népegészségügy, 38, pp. 26 - 38

HORVATH LG, 1955, 'Effect of fatigue on city workers.', Népegészségügy, 36, pp. 212 - 217

2022, 'A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS5101 - TPS5101, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5101

2022, 'Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.150

2022, 'CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS198

2022, 'Circulating tumour DNA (ctDNA) dynamics, CEA and sites of recurrence for the randomised DYNAMIC study: Adjuvant chemotherapy (ACT) guided by ctDNA analysis in stage II colon cancer (CC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S683 - S683, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.456

2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5027 - 5027, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5027

2022, 'Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of Lu-177-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301444&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2022, 'DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.TPS284

2022, 'DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. TPS5103 - TPS5103, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.tps5103

2022, 'Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1189 - S1189, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000866211601666&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2022, 'Genetic testing in prostate cancer: a scoping literature review', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 18, pp. 179 - 180, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000871956500285&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2022, 'Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.154

2022, 'Outcomes of appendiceal cancer treated at a state peritonectomy service.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301169&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2022, 'Outcomes of appendiceal cancer treated at a state peritonectomy service.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 3629 - 3629, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.3629

2022, 'PRINCE: Phase I trial of ¹⁷⁷Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 5017 - 5017, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.5017

2022, 'Patient-derived explant model of appendiceal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680301323&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2022, 'Patient-derived explant model of appendiceal cancer.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 4160 - 4160, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.4160

2022, 'Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.153

2022, 'Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 33, pp. S1322 - S1322, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 09 September 2022 - 13 September 2022, http://dx.doi.org/10.1016/j.annonc.2022.07.1791

2022, 'Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. LBA5004 - LBA5004, http://dx.doi.org/10.1200/jco.2022.40.17_suppl.lba5004

2021, 'A psychometric comparison of three approaches to chemotherapy-induced peripheral neuropathy assessment: Patient report, clinical grading, and sensory function', in QUALITY OF LIFE RESEARCH, SPRINGER, pp. S96 - S96, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000712224700205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2021, 'Association of ceramide metabolism with resistance to androgen receptor signalling inhibitors in metastatic prostate cancer', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S666 - S667, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1148

2021, 'CheckMate 9KD Arm B final analysis: Efficacy and safety of nivolumab plus docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.12

2021, 'DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS266

2021, 'Impact of combined lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S642 - S643, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1109

2021, 'PRINCE: Interim analysis of the phase Ib study of Lu-177-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 32, pp. S626 - S627, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1090

2021, 'Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.TPS183

2021, 'Plasma cell-free DNA profiling of PI3K/Akt pathway aberrations in two multi-institutional independent metastatic castration-resistant prostate cancer (mCRPC) cohorts.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.159

2021, African-specific prostate cancer molecular taxonomy, , http://dx.doi.org/10.21203/rs.3.rs-1122619/v1

2020, 'A phase I study of APL-501, an anti-PD-1 antibody, in patients with recurrent or advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368305113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S465 - S466, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.644

2020, 'DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, Vol. 31, pp. S548 - S549, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.2088

2020, 'Evaluation of a mainstream model of genetic testing for men with prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 16, pp. 40 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000594482700020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Lipidomic analysis of circulating lipids across the natural history of prostate cancer identifies aberrant ceramide metabolism', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, Vol. 80, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4761

2020, 'PHASE 1 STUDY OF AMG 160, A HALF-LIFE EXTENDED BITE (R) (BISPECIFIC T-CELL ENGAGER) THERAPY TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMJ PUBLISHING GROUP, pp. A207 - A208, http://dx.doi.org/10.1136/jitc-2020-SITC2020.0340

2020, 'Patient reported outcome scores used in chemotherapy-induced peripheral neuropathy: Defining minimal important differences', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, ELECTR NETWORK, Vol. 25, pp. 481 - 481, presented at Virtual Conference of Peripheral-Nerve-Society, ELECTR NETWORK, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000596008100112&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368309164&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. TPS5590 - TPS5590, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5590

2020, 'Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 38, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368309163&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. TPS5589 - TPS5589, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.tps5589

2020, 'Phospholipid profiling of clinical prostate tissues reveals targetable alterations in membrane lipid composition accompanying tumorigenesis', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-2076

2020, 'Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 38, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900245&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2020, 'Plasma cell-free DNA (cfDNA) profiling of copy number variation (CNV) to identify poor prognostic biomarkers in metastatic castration-resistant prostate cancer (mCRPC).', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 38, pp. 176 - 176, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.176

2020, 'Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S507 - S507, presented at ESMO Virtual Congress, ELECTR NETWORK, 19 September 2020 - 18 October 2020, http://dx.doi.org/10.1016/j.annonc.2020.08.869

2020, 'Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S1283 - S1283, presented at ESMO Asia Virtual Congress, ELECTR NETWORK, 20 November 2020 - 22 November 2020, http://dx.doi.org/10.1016/j.annonc.2020.10.127

2019, 'A phase 1 study of FPT155, a first-in-class CD80 extracellular domain-Fc fusion protein, in patients with advanced solid tumors', in JOURNAL FOR IMMUNOTHERAPY OF CANCER, BMC, Vol. 7, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000496473200862&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, Vol. 30, pp. 353 - 353, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295502322&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced tumors: Preliminary results from ongoing phase I studies.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2604

2019, 'Abstract CT084: Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in Clinical Trials, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-ct084

2019, 'Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.230

2019, 'FPT155-001: A phase Ia/Ib study of FPT155 (CD80-FC) in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.8_suppl.TPS42

2019, 'Health-related quality of life (HRQL) in a randomized phase III trial of enzalutamide with standard first-line therapy for metastatic, hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led, international, co-operative group trial', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 886 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295500177&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Long-term exposure (LTE) to Tislelizumab, an investigational anti-PD-1 antibody, in a first-in-human Phase I study', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, Vol. 79, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-CT084

2019, 'Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, Vol. 37, presented at ASCO-SITC Clinical Immuno-Oncology Symposium, CA, San Francisco, 28 February 2019 - 02 March 2019, http://dx.doi.org/10.1200/JCO.2019.37.7_suppl.TPS331

2019, 'Novel Targets for an In Vivo DC Anti-Prostate Cancer Vaccine', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Pharmacodynamics Effects of CDK4/6 Inhibitor LEE011 (Ribociclib) in High-Risk, Localised Prostate Cancer: A Study Protocol for a Randomised Controlled Phase II Trial (Leep Study)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 64 - 64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 32 - 33, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000476915200010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, 'Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (Id) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Barcelona, pp. 166 - +, presented at 44th Congress of the European-Society-for-Medical-Oncology (ESMO), SPAIN, Barcelona, 27 September 2019 - 01 October 2019, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000491295501268&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2019, DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis, , http://dx.doi.org/10.1101/865626

2018, 'An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 36, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.54

2018, 'Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 71 - 72, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100050&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2018, 'Correlating whole blood AR-V7 and AR-V9 with therapy response to AR-targeted therapies in metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.e17070

2018, 'P53 as a Predictor of Clinical Outcome in Localised Prostate Cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 65 - 66, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100038&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2018, 'P53 as a predictor of clinical outcome in localized prostate cancer.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 36, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.57

2018, 'Post Hoc Analysis of a Phase III Study to Test the Association Between Circulating Methylated Glutathione S Transferase (mGSTP1) DNA Levels and Response to Docetaxel (DTX) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 51 - 52, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000439493100013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2018, 'The Clinical Impact of Treating Localised Prostate Cancer - The Australian Experience', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 14, pp. 47 - 47, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437670700052&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2018, 'Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, Vol. 36, presented at Genitourinary Cancers Symposium, CA, San Francisco, 08 February 2018 - 10 February 2018, http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.252

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', in ANNALS OF ONCOLOGY, OXFORD UNIV PRESS, SPAIN, Madrid, presented at 42nd European-Society-for-Medical-Oncology Congress (ESMO), SPAIN, Madrid, 08 September 2017 - 12 September 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000411324001049&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Timmins HC; Li T; Kiernan MC; Horvath LG; Harrison M; Grimison P; Cox KM; Boyle FM; Goldstein D; Park SB, 2017, 'NEUROPHYSIOLOGICAL MEASURES CORRELATE WITH PATIENT REPORTED SYMPTOMS OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY', in JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, WILEY, SPAIN, Sitges, Vol. 22, pp. 395 - 396, presented at Peripheral-Nerve-Society Meeting, SPAIN, Sitges, 08 July 2017 - 12 July 2017, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000409243500424&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zhang A; Grogan J; Mahon K; Rasiah K; Sved P; Eisinger D; Boulas J; Vasilaris A; Henshall S; Stricker P; Kench J; Horvath L, 2017, 'A PROSPECTIVE MULTI-CENTER PHASE III VALIDATION STUDY OF AZGP1 AS A BIOMARKER IN LOCALISED PROSTATE CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, Vol. 13, pp. 64 - 64, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427541700115&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

2017, 'Abstract CT002: A Phase IB study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. CT002 - CT002, presented at Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC, http://dx.doi.org/10.1158/1538-7445.am2017-ct002

2017, 'Whole blood assay for rapid detection of AR-v7 in metastatic castration-resistant prostate cancer: No correlation with response to androgen-axis targeting agents.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, FL, Orlando, pp. 78 - 78, presented at AACR Special Conference on Prostate Cancer - Advances in Basic, Translational, and Clinical Research, FL, Orlando, 02 December 2017 - 05 December 2017, http://dx.doi.org/10.1158/1538-7445.PRCA2017-A098

Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler M; Briscoe K; Marx G; Horvath LG, 2016, 'Validation of circulating microRNA biomarkers of docetaxel outcome in castration-resistant prostate cancer', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, Vol. 118, pp. 22 - 22, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381708200046&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Lin H-M; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler M; Briscoe K; Marx G; Breit SN; Brown D; Horvath L, 2016, 'PHASE II TRIAL OF CIRCULATING CYTOKINES AS MARKERS OF DOCETAXEL RESISTANCE IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (mCRPC)', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, Vol. 12, pp. 37 - 37, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000380004900039&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Lin HM; Spielman C; Lee-Ng M; Gurney H; Mallesara G; Stockler M; Briscoe K; Marx G; Breit SN; Brown DA; Horvath LG, 2016, 'Phase II trial of circulating cytokines as markers of docetaxel resistance in metastatic castrateresistant prostate cancer (mCRPC)', in BJU INTERNATIONAL, WILEY-BLACKWELL, AUSTRALIA, Melbourne, Vol. 118, pp. 21 - 21, presented at 17th Asia-Pacific Prostate Cancer Conference, AUSTRALIA, Melbourne, 31 August 2016 - 03 September 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000381708200045&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler M; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark S; Swarbrick A; Daly R; Horvath L, 2014, 'CIRCULATING MICRORNAS ASSOCIATED WITH DOCETAXEL-RESISTANT CASTRATION-RESISTANT PROSTATE CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 26 - 27, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716200012&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes R; Chatfield MD; Boyer MJ; Stockler MR; Marx GM; Gurney H; Gowda GM H; Molloy P; Horvath L; Clark SJ, 2014, 'Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.11

Nagrial A; Chin V; Steinmann A; Chou A; Grimmond S; Horvath L; Pajic M; Biankin A, 2014, 'GENOMIC CLASSIFIER FOR PANCREATIC DUCTAL ADENOCARCINOMA THERAPEUTIC RESPONSE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 44 - 44, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Zhang AY; Butler LM; Stricker PD; Kench JG; Tilley WD; Sebastian L; Stockler M; Horvath L, 2014, 'PHARMACODYNAMIC EFFECTS OF THE HEAT SHOCK PROTEIN 90 (HSP90) INHIBITOR, AUY922, IN HIGH-RISK, LOCALISED PROSTATE CANCER', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 46 - 46, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716200068&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Horvath L; Chatfield MD; Lee-Ng M; Lin H-M; Castillo L; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockier MR; Wykes R; Henshall SM; Mahon KL, 2013, 'The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2013 - 04 June 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000335419605294&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mahon K; Chatfield M; Breit S; Brown D; Molloy M; Marx G; Pavlakis N; Boyer M; Stockler M; Horvath L, 2013, 'The role of macrophages in Docetaxel (DTX) resistance in castrate resistant prostate cancer (CRPC)', in BJU INTERNATIONAL, WILEY-BLACKWELL, pp. 30 - 31, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000321969100078&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee BY; Hochgraefe F; Lin HM; Castillo L; Raftery M; Horvath LG; Daly RJ, 2012, 'Overcoming Docetaxel Resistance in Prostate Cancer by Targeting FAK Phosphorylation, and Its Mode of Action', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, pp. 48 - 49, presented at 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, IRELAND, European Org Res & Treatment Canc (EORTC), Dublin, 06 November 2012 - 09 November 2012, http://dx.doi.org/10.1016/S0959-8049(12)71956-1

Moore MM; Chua W; Zhao J; Clarke SJ; Horvath L, 2009, 'Evaluation of plasma total and cleaved cytokeratin 18 as predictive markers of chemotherapy in colorectal cancer', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, FL, Orlando, 29 May 2009 - 02 June 2009, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000276606601162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Thanigasalam R; Rasiah K; Stricker P; Earnest A; Haynes AM; Sutherland S; Sutherland RL; Henshall S; Horvath L, 2008, 'Analysis of stage migration in localised prostate cancer in Australia and its impact on the post radical prostatectomy Kattan nomogram', in British Journal of Urology, WILEY-BLACKWELL, Hong Kong, PEOPLES R CHINA, pp. 35 - 35, presented at British Journal of Urology, Hong Kong, PEOPLES R CHINA, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000252815500114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a